Neukolln Onkologie Hamatologie Palliativmedizin

Vivantes Klinikum

Pathologic Constriction

Coronary Stenosis

Hemophilia A

Myocardial Ischemia

Oropharyngeal Cancer

Lymphoma

Coronary Artery Disease

Heart Valve Diseases

Schizophrenia

Heart Failure

Cisplatin

Obinutuzumab

Biotronik

Cardionovum

Nuwellis

Octapharma

Otsuka

Heidelberg University

Lisette Nixon

condition

Follicular Lymphoma

allSponsorName

Roche

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

Combined modality approach using Obitunuzumab and involved site low dose irradiation in early stage nodal follicular lymphoma. Radiation dose will be adapted for low-responders.

Primary Objective:

Evaluation of the rate of metabolic CR after low-dose involved site radiotherapy in combination with Gazyvaro (Obinutuzumab) in early stage nodal follicular lymphoma in order to avoid conventional full dose IF radiotherapy.

Secondary Objective:

Efficacy and safety of a response adapted radiation dose treatment schedule.

Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma

Vivantes Klinikum | Neukolln Onkologie Hamatologie Palliativmedizin

Site insights

Work at this site?

Active trials

Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma (GAZAI)

Trial sponsors